Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 5,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Random Match Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess TEV-56286 at Different Doses in Healthy Participants

NCT07674940
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TEV-56286, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

NCT02310750
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Prucalopride For Functional Constipation in Children and Teenagers

NCT04759833
View directory record Official record
Conditions
Constipation
Interventions
Prucalopride, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
6 Months to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

NCT02342249
View directory record Official record
Conditions
Influenza A
Interventions
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
129
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

NCT01789476
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Results available

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

NCT05227118
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elpipodect, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
65 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Santa Ana, California • Cutler Bay, Florida • Hallandale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

NCT03120520
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

NCT01792635
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
El Cajon, California • Encino, California • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
n-3 polyunsaturated fatty acids, Placebo
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 25, 2026, 6:15 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

NCT03056690
View directory record Official record
Conditions
Fibromyalgia
Interventions
ASP0819, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • El Cajon, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

NCT03200340
View directory record Official record
Conditions
Stomatitis
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Acetazolamide Efficacy in Ataxia in PMM2-CDG

NCT04679389
View directory record Official record
Conditions
Pmm2-CDG, CDG1A
Interventions
Placebo, Acetazolamide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 25, 2026, 6:15 AM EDT
Recruiting Early Phase 1 Interventional

Propranolol for Misophonia

NCT07271485
View directory record Official record
Conditions
Misophonia, Propanolol, Misophonia Treatment
Interventions
propranolol, Placebo
Drug
Lead sponsor
Bloom Mental Health, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

NCT01786915
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia 10mg, Bendavia 50mg, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 25, 2026, 6:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Almond on Facial Skin Collagen and Wrinkles

NCT06074276
View directory record Official record
Conditions
Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 25, 2026, 6:15 AM EDT